NASDAQ:ARDX

Ardelyx (ARDX) Stock Forecast, Price & News

$4.11

+0.03 (+0.74%)

(As of 02:39 PM ET)

Compare

Today's Range: $3.98
▼
$4.24
50-Day Range: $3.44
▼
$4.83
52-Week Range: $1.16
▼
$5.13

Volume: 2.65 million shs
Average Volume: 6.05 million shs
Market Capitalization: $895.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.25

Ardelyx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 99.8% Upside
$8.25 Price Target
Short Interest: Bearish
11.25% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.32
Upright™ Environmental Score
News Sentiment: 1.12
Based on 2 Articles This Week
Insider Trading: Selling Shares
$97,561 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.38) to ($0.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

262nd out of 969 stocks

Pharmaceutical Preparations Industry

103rd out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Ardelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.25, Ardelyx has a forecasted upside of 99.8% from its current price of $4.13.
Amount of Analyst Coverage
Ardelyx has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.25% of the outstanding shares of Ardelyx have been sold short.
Short Interest Ratio / Days to Cover
Ardelyx has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Ardelyx has recently decreased by 4.89%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ardelyx does not currently pay a dividend.
Dividend Growth
Ardelyx does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ardelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.
Environmental Sustainability
The Environmental Impact score for Ardelyx is -1.32.

3.4

News and Social Media Coverage

News Sentiment
Ardelyx has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ardelyx this week, compared to 2 articles on an average week.
Search Interest
41 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.
MarketBeat Follows
15 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,561.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Ardelyx is held by insiders.
Percentage Held by Institutions
58.19% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ardelyx are expected to grow in the coming year, from ($0.38) to ($0.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ardelyx is -14.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ardelyx is -14.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ardelyx has a P/B Ratio of 8.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Price History

30 days | 90 days | 365 days | Advanced Chart

ARDX Stock News Headlines

September 28, 2023 | finance.yahoo.com

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

September 25, 2023 | markets.businessinsider.com

Ardelyx Says Japan Approves Tenapanor For Hyperphosphatemia

October 2, 2023 | Goldco (Ad)

Ben Stein FREE Report: How Americans Are RUINING Retirement

There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!

September 24, 2023 | americanbankingnews.com

Ardelyx (NASDAQ:ARDX) Shares Gap Up to $3.66

September 14, 2023 | msn.com

Wedbush Reiterates Ardelyx (ARDX) Outperform Recommendation

September 12, 2023 | markets.businessinsider.com

Analyst Expectations for Ardelyx's Future

September 11, 2023 | markets.businessinsider.com

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

September 11, 2023 | finance.yahoo.com

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

September 8, 2023 | benzinga.com

Ardelyx Stock (NASDAQ:ARDX), Analyst Ratings, Price Targets, Predictions

September 8, 2023 | finance.yahoo.com

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 8, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Ardelyx (ARDX) with Buy Recommendation

September 6, 2023 | finance.yahoo.com

Unraveling Ardelyx Inc (ARDX): A Deep Dive into Its Performance Metrics

September 6, 2023 | finance.yahoo.com

Is Ardelyx (ARDX) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

September 1, 2023 | msn.com

Ardelyx (ARDX) Price Target Increased by 18.82% to 8.59

August 25, 2023 | msn.com

Cantor Fitzgerald Upgrades Ardelyx (ARDX)

August 25, 2023 | msn.com

Cantor upgrades Ardelyx to overweight ahead of FDA decision on renal drug

August 25, 2023 | msn.com

Ardelyx (NASDAQ:ARDX) Jumps With Likely New Drug Approval

August 15, 2023 | markets.businessinsider.com

Grabar Law Office Investigates Claims on Behalf of Shareholders of Ardelyx Inc. (ARDX)

August 10, 2023 | seekingalpha.com

Ardelyx, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 4, 2023 | finance.yahoo.com

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Call Transcript

August 3, 2023 | finance.yahoo.com

Forecast: Analysts Think Ardelyx, Inc.'s (NASDAQ:ARDX) Business Prospects Have Improved Drastically

August 2, 2023 | markets.businessinsider.com

Ardelyx Q2 Loss Narrows

August 2, 2023 | finanznachrichten.de

Ardelyx, Inc.: Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

August 2, 2023 | washingtonpost.com

Ardelyx: Q2 Earnings Snapshot

August 2, 2023 | finance.yahoo.com

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

July 31, 2023 | msn.com

Ardelyx: Niche Products For Competitive Markets

See More Headlines

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings: 8/02/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARDX
CUSIP: N/A
CIK: 1437402
Web: www.ardelyx.com
Phone: (510) 745-1700
Fax: 510-745-0493
Employees: 133
Year Founded: 2007

Price Target and Rating

Average Stock Price Forecast: $8.25
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +102.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,210,000.00
Net Margins: -67.69%
Pretax Margin: -67.67%
Return on Equity: -54.22%
Return on Assets: -29.41%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.63
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $52.16 million
Price / Sales: 17.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 8.16

Miscellaneous

Outstanding Shares: 217,860,000
Free Float: 205,881,000
Market Cap: $888.87 million
Optionable: Optionable
Beta: 1.17

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Michael G. Raab (Age 58)
Pres, CEO & Director
Comp: $1.28M

Ms. Susan Rodriguez (Age 59)
Chief Commercial Officer
Comp: $760.77k

Dr. Laura A. Williams M.D. (Age 59)
M.P.H., Chief Medical Officer
Comp: $873.8k

Mr. Justin A. Renz CPA (Age 51)
M.S.T., MBA, MST, Chief Financial & Operations Officer and Treasurer

Mr. Robert Felsch
Sr. VP of Fin. & Chief Accounting Officer

Ms. Elizabeth A. Grammer Esq. (Age 59)
Chief Legal & Admin. Officer and Sec.

Ms. Caitlin Lowie
VP of Corp. Communications & Investor Relations

Ms. Charon Spencer Sr.
Chief HR Officer

Mr. David P. Rosenbaum (Age 62)
Chief Devel. Officer

Mr. Robert C. Blanks (Age 63)
Chief Regulatory Affairs & Quality Assurance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.
What is Ardelyx's stock price forecast for 2023?: 6 Wall Street analysts have issued twelve-month price targets for Ardelyx's stock. Their ARDX share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.
How have ARDX shares performed in 2023?: Ardelyx's stock was trading at $2.85 at the beginning of the year. Since then, ARDX shares have increased by 43.2% and is now trading at $4.08.
View the best growth stocks for 2023 here.
When is Ardelyx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ARDX earnings forecast.
How were Ardelyx's earnings last quarter?: Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The biopharmaceutical company had revenue of $22.33 million for the quarter, compared to analyst estimates of $15.88 million. Ardelyx had a negative net margin of 67.69% and a negative trailing twelve-month return on equity of 54.22%.
What ETFs hold Ardelyx's stock?: ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).
What is Ardelyx's stock symbol?: Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How do I buy shares of Ardelyx?: Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ardelyx's stock price today?: One share of ARDX stock can currently be purchased for approximately $4.08.
How much money does Ardelyx make?: Ardelyx (NASDAQ:ARDX) has a market capitalization of $888.87 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.
How many employees does Ardelyx have?: The company employs 133 workers across the globe.
How can I contact Ardelyx?: Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ardelyx (ARDX) Stock Forecast, Price & News

Ardelyx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ardelyx (NASDAQ:ARDX) Stock

ARDX Price History

ARDX Stock News Headlines

ARDX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ARDX Stock - Frequently Asked Questions

Overall MarketRank^™